These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 25844949)
21. Development of a novel recombinant influenza vaccine in insect cells. McPherson CE Biologicals; 2008 Nov; 36(6):350-3. PubMed ID: 18804387 [TBL] [Abstract][Full Text] [Related]
22. Trypsin promotes efficient influenza vaccine production in MDCK cells by interfering with the antiviral host response. Seitz C; Isken B; Heynisch B; Rettkowski M; Frensing T; Reichl U Appl Microbiol Biotechnol; 2012 Jan; 93(2):601-11. PubMed ID: 21915610 [TBL] [Abstract][Full Text] [Related]
23. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines. Hu AY; Weng TC; Tseng YF; Chen YS; Wu CH; Hsiao S; Chou AH; Chao HJ; Gu A; Wu SC; Chong P; Lee MS Vaccine; 2008 Oct; 26(45):5736-40. PubMed ID: 18761387 [TBL] [Abstract][Full Text] [Related]
24. Development of a high-yield reassortant influenza vaccine virus derived from the A/Anhui/1/2013 (H7N9) strain. Nakamura K; Shirakura M; Suzuki Y; Naito T; Fujisaki S; Tashiro M; Nobusawa E Vaccine; 2016 Jan; 34(3):328-33. PubMed ID: 26657023 [TBL] [Abstract][Full Text] [Related]
26. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Schmeisser F; Vodeiko GM; Lugovtsev VY; Stout RR; Weir JP Vaccine; 2010 Mar; 28(12):2442-9. PubMed ID: 20074687 [TBL] [Abstract][Full Text] [Related]
27. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Cox MM; Izikson R; Post P; Dunkle L Ther Adv Vaccines; 2015 Jul; 3(4):97-108. PubMed ID: 26478817 [TBL] [Abstract][Full Text] [Related]
28. A flow-through chromatography process for influenza A and B virus purification. Weigel T; Solomaier T; Peuker A; Pathapati T; Wolff MW; Reichl U J Virol Methods; 2014 Oct; 207():45-53. PubMed ID: 24992667 [TBL] [Abstract][Full Text] [Related]
29. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791 [TBL] [Abstract][Full Text] [Related]
30. Influenza vaccines: from whole virus preparations to recombinant protein technology. Huber VC Expert Rev Vaccines; 2014 Jan; 13(1):31-42. PubMed ID: 24192014 [TBL] [Abstract][Full Text] [Related]
31. A pandemic influenza vaccine in India: from strain to sale within 12 months. Dhere R; Yeolekar L; Kulkarni P; Menon R; Vaidya V; Ganguly M; Tyagi P; Barde P; Jadhav S Vaccine; 2011 Jul; 29 Suppl 1():A16-21. PubMed ID: 21684421 [TBL] [Abstract][Full Text] [Related]
32. Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin. Schwarzer J; Rapp E; Hennig R; Genzel Y; Jordan I; Sandig V; Reichl U Vaccine; 2009 Jul; 27(32):4325-36. PubMed ID: 19410619 [TBL] [Abstract][Full Text] [Related]
33. New technologies for new influenza vaccines. Shaw A Vaccine; 2012 Jul; 30(33):4927-33. PubMed ID: 22579861 [TBL] [Abstract][Full Text] [Related]
34. Vaccine process technology. Josefsberg JO; Buckland B Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777 [TBL] [Abstract][Full Text] [Related]
35. Global production capacity of seasonal influenza vaccine in 2011. Partridge J; Kieny MP Vaccine; 2013 Jan; 31(5):728-31. PubMed ID: 23149268 [TBL] [Abstract][Full Text] [Related]
37. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses. Kiseleva I; Dubrovina I; Fedorova E; Larionova N; Isakova-Sivak I; Bazhenova E; Pisareva M; Kuznetsova V; Flores J; Rudenko L Vaccine; 2015 Dec; 33(49):7008-14. PubMed ID: 26432909 [TBL] [Abstract][Full Text] [Related]
38. Development of pandemic influenza vaccine production capacity in Viet Nam. Hoa LK; Hiep LV; Be LV Vaccine; 2011 Jul; 29 Suppl 1():A34-6. PubMed ID: 21684426 [TBL] [Abstract][Full Text] [Related]
39. Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine. Li C; Xu K; Hashem A; Shao M; Liu S; Zou Y; Gao Q; Zhang Y; Yuan L; Xu M; Li X; Wang J Hum Vaccin Immunother; 2015; 11(6):1351-6. PubMed ID: 25970793 [TBL] [Abstract][Full Text] [Related]
40. Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs. Ridenour C; Johnson A; Winne E; Hossain J; Mateu-Petit G; Balish A; Santana W; Kim T; Davis C; Cox NJ; Barr JR; Donis RO; Villanueva J; Williams TL; Chen LM Influenza Other Respir Viruses; 2015 Sep; 9(5):263-70. PubMed ID: 25962412 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]